Revolutionizing Small Molecule API Production: Unveiling The Impact Of Fermentation As A Sustainable Solution

By Jose Luis Barredo, General Manager and Head of Global Fermentation, Curia

While large molecules are making strides in drug development, small molecule Active Pharmaceutical Ingredients (APIs) continue to dominate New Drug Applications (NDAs). However, recent years have seen a convergence of traditional chemical synthesis for small molecule APIs and the biofermentation methods used for large molecules. The production of small molecule drug substances using recombinant hosts is gaining traction, driven by technological advances that have expanded the use of fermentation across various applications.

This white paper delves into the transformative impact of synthetic biology and related technologies on modern fermentation practices. Specific topics include:

• The Changing Landscape of Drug Development: Understand how fermentation is reshaping the pharmaceutical industry, merging the realms of small molecule APIs and large molecule biofermentation.
• Advantages of Fermentation: Uncover the benefits of fermentation, from novel molecule creation to flexible synthesis, sustainability, and cost-effectiveness.
• Technological Progress in Fermentation: Discover how synthetic biology and advanced analytical tools are boosting yields, reducing timelines, and enhancing process control.
• Curia’s Fermentation Expertise: See real-world case studies highlighting Curia’s strengths in synthetic biology, strain improvement, scaling, and downstream processing across diverse sectors.
• The Promising Future: Learn about the future of biopharmaceutical fermentation, powered by breakthroughs in molecular biology and engineering, offering sustainable solutions for a wide range of applications.

Stay ahead of the curve—download our white paper now to gain essential insights into the future of fermentation in drug development.